论文部分内容阅读
目的:探讨糖尿病心脏自主神经病变采用参松养心胶囊治疗对患者心率变异性的影响。方法:选择2013年6月—2015年6月在我院治疗的糖尿病心脏自主神经病变患者60例的临床资料进行回顾性分析。其中24例患者在控制血糖治疗的基础上给予腺苷钴胺治疗为对照组,36例患者在控制血糖治疗的基础上给予参松养心胶囊治疗为研究组。比较两组患者的临床疗效。结果:研究组及对照组治疗后SDNN、SDANN、r MSSD、PNN50、LF、HF及LF/HF较治疗前均显著升高,差异有统计学意义(P<0.05或P<0.01);治疗后两组间比较,差异无统计学意义(P>0.05)。两组治疗前后空腹血糖、餐后2 h血糖、Hg A1c、血脂水平及尿白蛋白排泄率水平比较差异无统计学意义(P>0.05);治疗后两组间比较,差异无统计学意义(P>0.05)。结论:参松养心胶囊治疗糖尿病心脏自主神经病变能够显著改善患者心率变异性,并且对血糖控制没有明显的不良影响,值得临床推广。
Objective: To investigate the effect of Shensongyangxin capsule on heart rate variability in patients with diabetic autonomic neuropathy. Methods: The clinical data of 60 patients with diabetic cardiac autonomic neuropathy treated in our hospital from June 2013 to June 2015 were retrospectively analyzed. Among them, 24 patients were given adenosylcobalamin as control group on the basis of controlling blood sugar, and 36 patients were treated by Shensongyangxin Capsule on the basis of controlling blood sugar. The clinical efficacy of the two groups was compared. Results: After treatment, SDNN, SDANN, MSSD, PNN50, LF, HF and LF / HF in study group and control group were significantly higher than those before treatment (P <0.05 or P <0.01) There was no significant difference between the two groups (P> 0.05). There were no significant differences in fasting blood glucose, postprandial blood glucose at 2 h, Hg A1c, blood lipid levels and urinary albumin excretion rate before and after treatment (P> 0.05). There was no significant difference between the two groups after treatment P> 0.05). Conclusion: Shensongyangxin Capsule for the treatment of diabetic autonomic neuropathy can significantly improve the patient’s heart rate variability, and has no obvious adverse effect on the control of blood glucose, which is worthy of clinical promotion.